$BBIO
BridgeBio Pharma, Inc. Stock $bbio

$bbio Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000095017022002030 Filed on February 25, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q1
Revenue	$1.694M	$12.89M	$462.0K
YoY Change	266.67%	10638.33%
Cost Of Revenue	$1.348M	$1.551M
YoY Change
Gross Profit	$346.0K	$11.34M
YoY Change
Gross Profit Margin	20.43%	87.96%
Selling, General & Admin	$43.71M	$54.75M	$45.41M
YoY Change	-3.73%	46.23%	32.54%
% of Gross Profit	12633.82%	483.01%
Research & Development	$107.6M	$122.2M	$122.6M
YoY Change	-12.17%	35.52%	79.64%
% of Gross Profit	31112.43%	1078.08%
Depreciation & Amortization	$1.884M	$1.526M	$566.0K
YoY Change	232.86%
% of Gross Profit	544.51%	13.46%
Operating Expenses	$151.4M	$176.9M	$168.0M
YoY Change	-9.89%	38.66%	63.89%
Operating Profit	-$173.7M	-$165.6M	-$167.5M
YoY Change	3.69%		63.44%
Interest Expense	$20.34M	-$14.95M	$9.738M
YoY Change	108.91%	42.26%	142.84%
% of Operating Profit
Other Income/Expense, Net	-$27.65M	$28.28M	-$3.578M
YoY Change	672.83%	849.13%	124.33%
Pretax Income	-$201.3M	-$152.3M	-$171.1M
YoY Change	17.68%	12.78%	64.37%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$201.3M	-$147.2M	-$171.1M
YoY Change	17.68%	22.67%	64.37%
Net Earnings / Revenue	-11884.89%	-1142.15%	-37030.74%
Basic Earnings Per Share	-$1.35
Diluted Earnings Per Share	-$1.346M	-$1.013M	-$1.176M
COMMON SHARES
Basic Shares Outstanding	147.6M	147.2M
Diluted Shares Outstanding	145.9M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$671.2M	$836.7M	$919.1M
YoY Change	-26.97%	37.81%	1.54%
Cash & Equivalents	$371.6M	$393.8M	$471.2M
Short-Term Investments	$299.7M	$442.9M	$447.9M
Other Short-Term Assets	$45.00M	$52.19M	$25.50M
YoY Change	76.49%	46.2%	28.79%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$716.2M	$888.9M	$945.1M
YoY Change	-24.22%	38.27%	2.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.18M	$30.07M	$35.80M
YoY Change	-52.01%	47.93%	45.53%
Goodwill
YoY Change
Intangibles	$30.48M	$44.93M
YoY Change
Long-Term Investments			$82.20M
YoY Change			254.31%
Other Assets	$35.33M	$33.03M	$30.20M
YoY Change	16.97%	38.01%	77.65%
Total Long-Term Assets	$96.92M	$123.9M	$148.2M
YoY Change	-34.6%	103.96%	128.7%
TOTAL ASSETS
Total Short-Term Assets	$716.2M	$888.9M	$945.1M
Total Long-Term Assets	$96.92M	$123.9M	$148.2M
Total Assets	$813.1M	$1.013B	$1.093B
YoY Change	-25.62%	43.95%	10.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.11M	$11.88M	$10.30M
YoY Change	-1.87%	32.86%	-21.37%
Accrued Expenses	$93.36M	$122.9M	$80.50M
YoY Change	15.97%	54.38%	66.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$295.0K	$3.646M
YoY Change		-79.77%
Total Short-Term Liabilities	$103.5M	$135.1M	$94.70M
YoY Change	9.25%	41.21%	45.92%
LONG-TERM LIABILITIES
Long-Term Debt	$434.1M	$430.8M	$1.363B
YoY Change	-68.14%	366.08%	195.4%
Other Long-Term Liabilities	$26.83M	$22.07M	$8.425M
YoY Change	218.45%	131.82%	-26.74%
Total Long-Term Liabilities	$460.9M	$452.8M	$8.425M
YoY Change	5371.13%	344.2%	-98.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$103.5M	$135.1M	$94.70M
Total Long-Term Liabilities	$460.9M	$452.8M	$8.425M
Total Liabilities	$1.854B	$1.878B	$1.489B
YoY Change	24.54%	215.32%	144.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.633B	-$1.437B	-$874.4M
YoY Change	86.79%	61.68%
Common Stock	$867.8M	$841.7M	$853.3M
YoY Change	1.7%	-17.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$275.0M	$275.0M
YoY Change		266.67%
Treasury Stock Shares	$6.192M	$6.192M	$3.175M
Shareholders Equity	-$1.041B	-$870.4M	-$395.3M
YoY Change
Total Liabilities & Shareholders Equity	$813.1M	$1.013B	$1.093B
YoY Change	-25.62%	43.95%	10.46%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q1
OPERATING ACTIVITIES
Net Income	-$201.3M	-$147.2M	-$171.1M
YoY Change	17.68%	22.67%	64.37%
Depreciation, Depletion And Amortization	$1.884M	$1.526M	$566.0K
YoY Change	232.86%
Cash From Operating Activities	-$160.6M	-$133.9M	-$150.8M
YoY Change	6.55%	39.1%	79.65%
INVESTING ACTIVITIES
Capital Expenditures	$859.0K	-$2.536M	$1.961M
YoY Change	-56.2%	17.95%	-56.2%
Acquisitions
YoY Change
Other Investing Activities	$139.5M	$24.34M	-$280.1M
YoY Change	-149.8%	-71.42%	-759.04%
Cash From Investing Activities	$138.6M	$21.80M	-$282.1M
YoY Change	-149.15%	-73.74%	-841.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$50.00M
YoY Change			-33.33%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-160.0K	325.4M	547.9M
YoY Change	-100.03%	7082.8%	24.76%
NET CHANGE
Cash From Operating Activities	-160.6M	-133.9M	-150.8M
Cash From Investing Activities	138.6M	21.80M	-282.1M
Cash From Financing Activities	-160.0K	325.4M	547.9M
Net Change In Cash	-22.17M	213.3M	115.1M
YoY Change	-119.26%	-2548.75%	-70.73%
FREE CASH FLOW
Cash From Operating Activities	-$160.6M	-$133.9M	-$150.8M
Capital Expenditures	$859.0K	-$2.536M	$1.961M
Free Cash Flow	-$161.5M	-$131.4M	-$152.7M
YoY Change	5.74%	39.58%	72.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020Q4	us-gaap	Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherNoncurrentAssetsMember
CY2021Q4	us-gaap	Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherNoncurrentAssetsMember
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAccruedLiabilitiesCurrent
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019Q4	us-gaap	Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherNoncurrentAssetsMember
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001743881
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Restricted Cash Current Asset Statement Of Financial Position Extensible List RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PrepaidExpensesAndOtherCurrentAssetsMember
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	3700000
CY2021Q4	us-gaap	Restricted Cash Current Asset Statement Of Financial Position Extensible List RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PrepaidExpensesAndOtherCurrentAssetsMember
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021	bbio	Short Term Marketable Securities Contractual Maturities ShortTermMarketableSecuritiesContractualMaturities	P6M
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-38959
CY2021	dei	Entity Registrant Name EntityRegistrantName	BridgeBio Pharma, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-1850815
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	421 Kipling Street
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Palo Alto
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94301
CY2021	dei	City Area Code CityAreaCode	650
CY2021	dei	Local Phone Number LocalPhoneNumber	391-9740
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021	dei	Trading Symbol TradingSymbol	BBIO
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	5000000000.0
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	147607820
CY2021	dei	Auditor Firm AuditorFirmId	34
CY2021	dei	Auditor Name AuditorName	DELOITTE & TOUCHE LLP
CY2021	dei	Auditor Location AuditorLocation	San Francisco, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	393772000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	356082000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	393743000
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	251011000
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	49148000
CY2021Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	19749000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	32446000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	35731000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	888858000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	642824000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30066000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20325000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15907000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16508000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	44934000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33027000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23931000
CY2021Q4	us-gaap	Assets Assets	1012792000
CY2020Q4	us-gaap	Assets Assets	703588000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11884000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8945000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	37041000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	29682000
CY2021Q4	bbio	Accrued Research And Development Liabilities Current AccruedResearchAndDevelopmentLiabilitiesCurrent	44138000
CY2020Q4	bbio	Accrued Research And Development Liabilities Current AccruedResearchAndDevelopmentLiabilitiesCurrent	27290000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6786000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5579000
CY2020Q4	bbio	Leo Call Option Liability Current LEOCallOptionLiabilityCurrent	5550000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4938000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3795000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1458000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	30282000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13349000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	135069000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	95648000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	430752000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	92421000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17428000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14677000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	22069000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9520000
CY2021Q4	us-gaap	Liabilities Liabilities	1878371000
CY2020Q4	us-gaap	Liabilities Liabilities	595702000
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	1423000
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	1630000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	153535084
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	147343323
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	125264070
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	122849389
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	154000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	125000
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	6191761
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	2414681
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	275000000
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	75000000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	841530000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1021344000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-132000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	192000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1436966000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-888755000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-870414000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	57906000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	3412000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	48350000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-867002000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	106256000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1012792000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	703588000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69716000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8249000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40560000
CY2021	bbio	Cost Of License Revenue CostOfLicenseRevenue	379000
CY2019	bbio	Cost Of License Revenue CostOfLicenseRevenue	2500000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2735000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	451024000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	337047000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	209947000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	192210000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	145684000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	94353000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	646348000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	482731000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	306800000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-576632000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-474482000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-266240000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	1133000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	4015000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	8915000
CY2021	us-gaap	Interest Expense InterestExpense	46778000
CY2020	us-gaap	Interest Expense InterestExpense	36655000
CY2019	us-gaap	Interest Expense InterestExpense	8765000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-20869000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35823000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1634000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1626000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9822000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-31006000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-22345000
CY2021	us-gaap	Profit Loss ProfitLoss	-586454000
CY2020	us-gaap	Profit Loss ProfitLoss	-505488000
CY2019	us-gaap	Profit Loss ProfitLoss	-288585000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-23915000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-56764000
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-27998000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-562539000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-448724000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-260587000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.90
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.80
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.48
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	144356619
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	117995457
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105099089
CY2021	us-gaap	Profit Loss ProfitLoss	-586454000
CY2020	us-gaap	Profit Loss ProfitLoss	-505488000
CY2019	us-gaap	Profit Loss ProfitLoss	-288585000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-324000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-62000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	254000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-586778000
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-505550000
CY2019	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-288331000
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-23915000
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-56764000
CY2019	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-27998000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-562863000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-448786000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-260333000
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	377240000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15198000
CY2019	bbio	Stock Issued During Repayment Of Nonrecourse Notes StockIssuedDuringRepaymentOfNonrecourseNotes	179000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	254000
CY2019	bbio	Issuance Repurchase Of Noncontrolling Interest IssuanceRepurchaseOfNoncontrollingInterest	1206000
CY2019	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-1803000
CY2019	bbio	Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss	-285707000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	473733000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36530000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	168078000
CY2020	bbio	Adjustments To Additional Paid In Capital Purchase Of Capped Calls AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls	-49280000
CY2020	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	75000000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-62000
CY2020	bbio	Issuance Repurchase Of Noncontrolling Interest IssuanceRepurchaseOfNoncontrollingInterest	50828000
CY2020	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-1843000
CY2020	bbio	Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss	-500930000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	106256000
CY2021Q4	bbio	Repurchase Of Noncontrolling Interests Transaction Costs RepurchaseOfNoncontrollingInterestsTransactionCosts	70734000
CY2021	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	-91997000
CY2021	bbio	Adjustments To Additional Paid In Capital Purchase Of Capped Calls AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls	-61295000
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	200000000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	89823000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-324000
CY2021	bbio	Issuance Repurchase Of Noncontrolling Interest IssuanceRepurchaseOfNoncontrollingInterest	6240000
CY2021	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	3455000
CY2021	bbio	Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss	-581129000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-867002000
CY2021	us-gaap	Profit Loss ProfitLoss	-586454000
CY2020	us-gaap	Profit Loss ProfitLoss	-505488000
CY2019	us-gaap	Profit Loss ProfitLoss	-288585000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	99505000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	58459000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	21374000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5843000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1456000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	859000
CY2021	bbio	Noncash Lease Expense NoncashLeaseExpense	5611000
CY2020	bbio	Noncash Lease Expense NoncashLeaseExpense	3088000
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	29914000
CY2021	us-gaap	Accretion Expense AccretionExpense	5795000
CY2020	us-gaap	Accretion Expense AccretionExpense	17737000
CY2019	us-gaap	Accretion Expense AccretionExpense	1509000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1197000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3338000
CY2021	bbio	Call Option Expense Income CallOptionExpenseIncome	-5550000
CY2020	bbio	Call Option Expense Income CallOptionExpenseIncome	1472000
CY2019	bbio	Call Option Expense Income CallOptionExpenseIncome	1069000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3337000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-20869000
CY2020	bbio	Fair Value Of Shares Issued Under License Agreements FairValueOfSharesIssuedUnderLicenseAgreements	6014000
CY2019	bbio	Fair Value Of Shares Issued Under License Agreements FairValueOfSharesIssuedUnderLicenseAgreements	220000
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	4727000
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	3560000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-7092000
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1225000
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	3547000
CY2021	bbio	Increase Decrease Receivable From Licensing And Collaboration Agreements IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements	19749000
CY2020	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-2845000
CY2019	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	2845000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4262000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7059000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10647000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	9816000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2146000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	16929000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2833000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-735000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4657000
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	13039000
CY2021	bbio	Purchase Of Capped Calls PurchaseOfCappedCalls	61295000
CY2020	bbio	Purchase Of Capped Calls PurchaseOfCappedCalls	49280000
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	200000000
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	75000000
CY2019	bbio	Proceeds From Issuance Of Noncontrolling Interest ProceedsFromIssuanceOfNoncontrollingInterest	23309000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	7378000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	8589000
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	9270000
CY2021	bbio	Increase Decrease In Accrued Research And Development Liabilities IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities	11178000
CY2020	bbio	Increase Decrease In Accrued Research And Development Liabilities IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities	6170000
CY2019	bbio	Increase Decrease In Accrued Research And Development Liabilities IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities	11981000
CY2021	bbio	Increase Decrease In Accrued Professional Service IncreaseDecreaseInAccruedProfessionalService	2157000
CY2020	bbio	Increase Decrease In Accrued Professional Service IncreaseDecreaseInAccruedProfessionalService	2407000
CY2019	bbio	Increase Decrease In Accrued Professional Service IncreaseDecreaseInAccruedProfessionalService	1450000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6122000
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3472000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	12007000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	8335000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1462000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-497934000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-399714000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-253587000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	589892000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	287852000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	212899000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	380200000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	249137000
CY2021	bbio	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	62691000
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	53383000
CY2021	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	34150000
CY2021	bbio	Proceeds From Consolidation Of Entities ProceedsFromConsolidationOfEntities	13654000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	35000000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13246000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7518000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2638000
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	6760000
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	1716000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200826000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-52993000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-217253000
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	366237000
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	747500000
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	550000000
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	16064000
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	124119000
CY2021	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	456296000
CY2019	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	36939000
CY2020	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	24094000
CY2019	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	23927000
CY2021	bbio	Proceeds From Issuance Of Noncontrolling Interests ProceedsFromIssuanceOfNoncontrollingInterests	3500000
CY2020	bbio	Proceeds From Issuance Of Noncontrolling Interests ProceedsFromIssuanceOfNoncontrollingInterests	2000000
CY2019	bbio	Proceeds From Issuance Of Noncontrolling Interests ProceedsFromIssuanceOfNoncontrollingInterests	1500000
CY2021	bbio	Repurchase Of Noncontrolling Interest Including Direct Transaction Costs RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts	85090000
CY2020	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	5000000
CY2019	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	55011000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3821000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1205000
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	921000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4746000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	714000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16643000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12923000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1788000
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-818000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	736446000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	447189000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	398792000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	37686000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5518000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-72048000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	358679000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	364197000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	436245000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	396365000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	358679000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	364197000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	29774000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	15322000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	6092000
CY2020	bbio	Deferred Merger Transaction Costs Included In Accounts Payable And Accrued Professional Services DeferredMergerTransactionCostsIncludedInAccountsPayableAndAccruedProfessionalServices	1842000
CY2021	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	2449000
CY2019	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	2097000
CY2021	bbio	Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest	-2124000
CY2020	bbio	Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest	12034000
CY2019	bbio	Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest	-28635000
CY2020	bbio	Recognition Of Property And Equipment Previously Classified In Other Assets RecognitionOfPropertyAndEquipmentPreviouslyClassifiedInOtherAssets	10000000
CY2021	bbio	Noncash Or Part Noncash Contributions Made By Noncontrolling Interests NoncashOrPartNoncashContributionsMadeByNoncontrollingInterests	21600000
CY2020	bbio	Noncash Or Part Noncash Contributions Made By Noncontrolling Interests NoncashOrPartNoncashContributionsMadeByNoncontrollingInterests	4727000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	563000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1101000
CY2021	bbio	Intangible Assets Recorded In Other Accrued And Other Long Term Liabilities IntangibleAssetsRecordedInOtherAccruedAndOtherLongTermLiabilities	12500000
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1120000
CY2019	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	8000000
CY2019	bbio	Fair Value Of Success Fee Derivative At Issuance Of Term Loan FairValueOfSuccessFeeDerivativeAtIssuanceOfTermLoan	1148000
CY2021	bbio	Net Non Cash Portion Of Repurchase Of Noncontrolling Interests NetNonCashPortionOfRepurchaseOfNoncontrollingInterests	38168000
CY2021	bbio	Direct Transaction Costs In Repurchase Of Noncontrolling Interest Recorded In Additional Paid In Capital Previously Classified In Prepaid Expenses And Other Current Assets DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets	8749000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Organization and Description of Business </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) was established to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio’s pipeline of programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the Company’s two approved therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 1, 2019, BridgeBio completed the 2019 Reorganization, whereby all unitholders of BridgeBio Pharma LLC (“BBP LLC”) exchanged their units for shares of common stock of BridgeBio, and BBP LLC became a wholly-owned subsidiary of BridgeBio, and closed the Initial Public Offering (“IPO”) of its common stock.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since inception, BridgeBio has either created wholly-owned subsidiaries or has made investments in certain controlled entities, including partially-owned subsidiaries for which BridgeBio has a majority voting interest, and variable interest entities (“VIEs”) for which BridgeBio is the primary beneficiary (collectively, “we”, “our”, “us”). BridgeBio is headquartered in Palo Alto, California.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The results of operations and cash flows prior to the IPO closing on July 1, 2019 relate to BBP LLC, its subsidiaries and controlled entities. Subsequent to the IPO closing, the information relates to BridgeBio, its subsidiaries and controlled entities. All share and per share amounts in these consolidated financial statements and related notes were retroactively adjusted, where applicable, for the comparable periods presented to give effect to the exchange ratio applied in connection with the 2019 Reorganization.</span>
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Presentation Reclassifications</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain reclassifications have been made to the consolidated statements of cash flows for the year ended December 31, 2020 and 2019 to conform to the current year’s presentation. These reclassifications had no net effect on cash flows from operating, financing and investing activities as previously reported.</span></p>
CY2021	bbio	Minimum Required Percentage Of Voting Interests Of Investee To Exercise Significant Influence MinimumRequiredPercentageOfVotingInterestsOfInvesteeToExerciseSignificantInfluence	0.20
CY2021	bbio	Impairment Charge On Equity And Cost Method Investments ImpairmentChargeOnEquityAndCostMethodInvestments	0
CY2020	bbio	Impairment Charge On Equity And Cost Method Investments ImpairmentChargeOnEquityAndCostMethodInvestments	0
CY2019	bbio	Impairment Charge On Equity And Cost Method Investments ImpairmentChargeOnEquityAndCostMethodInvestments	0
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">accruals for research and development activities and contingent clinical, development, regulatory, and sales-based milestone payments in our in-licensing agreements and asset acquisitions, </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">accruals for performance-based milestone compensation arrangements, </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">accounting for stock-based award modifications, </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the present value of lease payments of our leases on the respective lease commencement dates, </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the expected recoverability and estimated useful lives of our long-lived assets, </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the fair value of the LEO call option liability up until its termination (see Note 7), and </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the fair value of the liability component of our </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% convertible senior notes due 2027 (the “2027 Notes”) in 2020 prior to our adoption of Accounting Standards Update (“ASU”) 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (“ASU 2020-06”, see succeeding section and Note 10). </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We base our estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	2600000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	2600000
CY2021	bbio	Cash Cash Equivalents And Restricted Cash Maturity Period CashCashEquivalentsAndRestrictedCashMaturityPeriod	P90D
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	393772000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	356082000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	363773000
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	177000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	139000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2416000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2458000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	424000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	396365000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	358679000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	364197000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3300000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	bbio	Number Of Business Segments NumberOfBusinessSegments	1
CY2021	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Capped Call Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2021 and March 2020, in connection with the issuance of the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% convertible senior notes due 2029 (the “</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2029 Notes”) and the 2027 Notes, respectively (see Note 10), BridgeBio entered into certain capped call transactions (the “Capped Call Transactions”). The Capped Call Transactions are generally expected to reduce the potential dilution to the holders of BridgeBio’s common stock upon any conversion of the Notes and/or offset any cash payments BridgeBio is required to make in excess of the principal amount of converted Notes, with such reduction and/or offset subject to a cap based on the cap price (see Note 10). The capped calls meet the conditions outlined in ASC 815-40, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, to be classified in stockholders’ equity as a reduction to additional paid-in capital and are not subsequently remeasured as long as the conditions for equity classification continue to be met.</span></p>
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9520000
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8425000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1021344000
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	853266000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-888755000
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-874427000
CY2021Q4	bbio	Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount	0
CY2020Q4	bbio	Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount	0
CY2020Q4	bbio	Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount	0
CY2021Q4	bbio	Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount	0
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	68538000
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	2206000
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	40830000
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	29914000
CY2020	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0
CY2019	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	233103000
CY2021Q4	bbio	Cash Equivalents Unrealized Losses CashEquivalentsUnrealizedLosses	-2000
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	233101000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	626976000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	134000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	626844000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	517256000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	196000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	517448000
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2020	bbio	Short Term Marketable Securities Contractual Maturities ShortTermMarketableSecuritiesContractualMaturities	P5M
CY2021	bbio	Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital	-2100000
CY2020	bbio	Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital	12000000.0
CY2019	bbio	Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital	-28600000
CY2021Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	2100000
CY2021	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P12Y9M18D
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	47500000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2566000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	44934000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2600000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	3700000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	3700000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	3700000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	3700000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	26100000
CY2021Q4	bbio	Potential Milestone Fixed Monetary Amount Settlement In Cash PotentialMilestoneFixedMonetaryAmountSettlementInCash	10799000
CY2021Q4	bbio	Potential Milestone Accrued Amount Settlement In Cash PotentialMilestoneAccruedAmountSettlementInCash	1045000
CY2021Q4	bbio	Potential Milestone Fixed Monetary Amount Settlement In Stock PotentialMilestoneFixedMonetaryAmountSettlementInStock	116481000
CY2021Q4	bbio	Potential Milestone Accrued Amount Settlement In Stock PotentialMilestoneAccruedAmountSettlementInStock	12247000
CY2021Q4	bbio	Potential Milestone Fixed Monetary Amount Settlement In Cash Or Stock At Sole Discretion PotentialMilestoneFixedMonetaryAmountSettlementInCashOrStockAtSoleDiscretion	114351000
CY2021Q4	bbio	Potential Milestone Accrued Amount Settlement In Cash Or Stock At Sole Discretion PotentialMilestoneAccruedAmountSettlementInCashOrStockAtSoleDiscretion	2394000
CY2021Q4	bbio	Potential Milestone Fixed Monetary Settlement Amount PotentialMilestoneFixedMonetarySettlementAmount	241631000
CY2021Q4	bbio	Potential Milestone Accrued Settlement Amount PotentialMilestoneAccruedSettlementAmount	15686000
CY2021Q4	bbio	Accrued Termination Charges AccruedTerminationCharges	0
CY2020Q4	bbio	Accrued Termination Charges AccruedTerminationCharges	0
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	29307000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3336000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	32643000
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	92500000
CY2020Q4	bbio	Debt Instrument Unamortized Discount Premium Debt Issuance Costs And End Of Term Fees Accretion DebtInstrumentUnamortizedDiscountPremiumDebtIssuanceCostsAndEndOfTermFeesAccretion	-1379000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	93879000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1458000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	92421000
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	600000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3971000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	459000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	5611000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	3786000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	402000
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	9000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	4243000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	832000
CY2021	us-gaap	Lease Cost LeaseCost	10256000
CY2020	us-gaap	Lease Cost LeaseCost	4627000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	6122000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	4169000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	272000
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	34000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6380000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	19595000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	1726000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M6D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0558
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0624
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0662
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0662
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6035000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	387000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5292000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	432000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4481000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	445000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-586478000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-505488000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-288585000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	24000
CY2021	us-gaap	Profit Loss ProfitLoss	-586454000
CY2020	us-gaap	Profit Loss ProfitLoss	-505488000
CY2019	us-gaap	Profit Loss ProfitLoss	-288585000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.256
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.250
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.253
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.039
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.033
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.041
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.012
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.010
CY2019	bbio	Effective Income Tax Rate Reconciliation Change In Entity Status EffectiveIncomeTaxRateReconciliationChangeInEntityStatus	0.017
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	0.014
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	331537000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	191308000
CY2021Q4	bbio	Deferred Tax Assets Amortization Of Assets DeferredTaxAssetsAmortizationOfAssets	9570000
CY2020Q4	bbio	Deferred Tax Assets Amortization Of Assets DeferredTaxAssetsAmortizationOfAssets	7427000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	8833000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5707000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10233000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5471000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	67724000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	37964000
CY2020Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	7608000
CY2021Q4	bbio	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	3821000
CY2020Q4	bbio	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	3932000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	448000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	613000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	432166000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	260030000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	423909000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	224452000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8257000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	35578000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	339000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	221000
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2844000
CY2020Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	32938000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8257000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	36673000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1095000
CY2017	bbio	Federal Net Operating Losses FederalNetOperatingLosses	37500000
CY2017	bbio	Federal Net Operating Losses Expiration Year FederalNetOperatingLossesExpirationYear	2035
CY2021	bbio	Federal Net Operating Losses FederalNetOperatingLosses	1500000000
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	3514000
CY2021Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	5074000
CY2021	bbio	Percentage Of Taxable Income Limitation In Utilization Of Operating Loss Carry Forward PercentageOfTaxableIncomeLimitationInUtilizationOfOperatingLossCarryForward	0.80
CY2021	bbio	Operating Loss Carryforwards Expiration Year OperatingLossCarryforwardsExpirationYear	2038
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	199500000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	95500000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	79200000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12524000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7604000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	4037000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	354000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	224000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5047000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5144000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	21254000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12524000
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	52252566
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29240319
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10722263
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1903000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	38000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4413000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	26095000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1761000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3729000
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	221000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	22366000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1540000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4938000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17428000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	22366000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	295000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1245000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1540000
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	2600000
CY2019Q4	bbio	One Time Fees Receivable Noncurrent OneTimeFeesReceivableNoncurrent	10000000.0
CY2021Q4	bbio	Payable Related To Manufacturing Suite PayableRelatedToManufacturingSuite	2000000.0
CY2020Q4	bbio	Payable Related To Manufacturing Suite PayableRelatedToManufacturingSuite	4000000.0
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	105574000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	58459000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21374000

Files In Submission

Name	View Source	Status
0000950170-22-002030-index-headers.html	Edgar Link	pending
0000950170-22-002030-index.html	Edgar Link	pending
0000950170-22-002030.txt	Edgar Link	pending
0000950170-22-002030-xbrl.zip	Edgar Link	pending
bbio-20211231.htm	Edgar Link	pending
bbio-20211231.xsd	Edgar Link	pending
bbio-20211231_cal.xml	Edgar Link	unprocessable
bbio-20211231_def.xml	Edgar Link	unprocessable
bbio-20211231_htm.xml	Edgar Link	completed
bbio-20211231_lab.xml	Edgar Link	unprocessable
bbio-20211231_pre.xml	Edgar Link	unprocessable
bbio-ex10_1.htm	Edgar Link	pending
bbio-ex10_30.htm	Edgar Link	pending
bbio-ex10_39.htm	Edgar Link	pending
bbio-ex21.htm	Edgar Link	pending
bbio-ex23_1.htm	Edgar Link	pending
bbio-ex31_1.htm	Edgar Link	pending
bbio-ex31_2.htm	Edgar Link	pending
bbio-ex32_1.htm	Edgar Link	pending
bbio-ex32_2.htm	Edgar Link	pending
bbio-ex4_3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img186147651_0.jpg	Edgar Link	pending
img186147651_1.jpg	Edgar Link	pending
img186147651_2.jpg	Edgar Link	pending
img186147651_3.jpg	Edgar Link	pending
img186147651_4.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BBIO
BridgeBio Pharma, Inc. Stock $bbio

2022 Q1 Form 10-K Financial Statement

#000095017022002030 Filed on February 25, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BBIO BridgeBio Pharma, Inc. Stock $bbio

2022 Q1 Form 10-K Financial Statement

#000095017022002030 Filed on February 25, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BBIO
BridgeBio Pharma, Inc. Stock $bbio